DE60134762D1 - Metabotropische glutamatrezeptor-antagonisten - Google Patents

Metabotropische glutamatrezeptor-antagonisten

Info

Publication number: DE60134762D1
Authority: DE; Germany
Prior art keywords: receptor antagonists; glutamate receptor; metabotropic glutamate; metabotropic; antagonists
Prior art date: 2000-10-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60134762T

Other languages

English (en)

Inventor

Dominique Jean-Pierre Mabire

Marc Gaston Venet

Sophie Coupa

Alain Philippe Poncelet

Anne Lesage

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceutica NV

Original Assignee

Janssen Pharmaceutica NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-02

Filing date

2001-09-25

Publication date

2008-08-21

2001-09-25 Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV

2008-08-21 Application granted granted Critical

2008-08-21 Publication of DE60134762D1 publication Critical patent/DE60134762D1/de

2021-09-26 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

DE60134762T 2000-10-02 2001-09-25 Metabotropische glutamatrezeptor-antagonisten Expired - Lifetime DE60134762D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00203419		2000-10-02
PCT/EP2001/011135 WO2002028837A1 (en)	2000-10-02	2001-09-25	Metabotropic glutamate receptor antagonists

Publications (1)

Publication Number	Publication Date
DE60134762D1 true DE60134762D1 (de)	2008-08-21

Family

ID=8172097

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60134762T Expired - Lifetime DE60134762D1 (de)	2000-10-02	2001-09-25	Metabotropische glutamatrezeptor-antagonisten

Country Status (28)

Country	Link
US (2)	US7115630B2 (de)
EP (1)	EP1332133B1 (de)
JP (1)	JP2004510764A (de)
KR (1)	KR100818965B1 (de)
CN (1)	CN1703403A (de)
AR (1)	AR035065A1 (de)
AT (1)	ATE400558T1 (de)
AU (2)	AU2001293847B2 (de)
BG (1)	BG107672A (de)
BR (1)	BR0114253A (de)
CA (1)	CA2421782A1 (de)
CZ (1)	CZ20031145A3 (de)
DE (1)	DE60134762D1 (de)
EA (1)	EA007464B1 (de)
EE (1)	EE05195B1 (de)
ES (1)	ES2309095T3 (de)
HR (1)	HRP20030229A2 (de)
HU (1)	HUP0302167A3 (de)
IL (2)	IL155163A0 (de)
MX (1)	MXPA03002907A (de)
MY (1)	MY147730A (de)
NO (1)	NO325079B1 (de)
NZ (1)	NZ524945A (de)
PL (1)	PL360677A1 (de)
SK (1)	SK5212003A3 (de)
UA (1)	UA76726C2 (de)
WO (1)	WO2002028837A1 (de)
ZA (1)	ZA200302515B (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA76726C2 (uk) *	2000-10-02	2006-09-15	Янссен Фармацевтика Н.В.	Метаботропічні антагоністи рецептора глутамату, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб її одержання
US7084156B2 (en) *	2001-11-27	2006-08-01	Merck & Co., Inc.	2-Aminoquinoline compounds
AU2002365611A1 (en)	2001-12-05	2003-06-17	F. Hoffmann - La Roche Ag	Inflammation modulators
US7452888B2 (en)	2002-03-27	2008-11-18	Glaxo Group Limited	Quinoline derivatives and their use as 5-ht6 ligands
WO2003082350A2 (en) *	2002-03-29	2003-10-09	Janssen Pharmaceutica N.V.	Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
US7964609B2 (en)	2002-06-20	2011-06-21	Astrazeneca Ab	Use of mGluR5 antagonists for the treatment of gerd
CA2505427C (en) *	2002-11-12	2012-04-03	Abbott Laboratories	Bicyclic-substituted amines as histamine-3 receptor ligands
US7153889B2 (en)	2002-11-12	2006-12-26	Abbott Laboratories	Bicyclic-substituted amines as histamine-3 receptor ligands
US7332508B2 (en) *	2002-12-18	2008-02-19	Novo Nordisk A/S	Substituted homopiperidine, piperidine or pyrrolidine derivatives
TW200523253A (en)	2003-07-22	2005-07-16	Arena Pharm Inc	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
CA2540021A1 (en) *	2003-09-26	2005-04-07	Rigel Pharmaceuticals, Inc.	Hcv inhibitors and methods of using them
EP1687277B1 (de)	2003-11-20	2018-04-04	Janssen Pharmaceutica NV	6-alkenyl- und 6-phenylalkylsubstituierte 2-chinolinone und 2-chinoxalinone als poly(adp-ribose)-polymerase-inhibitoren
EA011211B1 (ru)	2003-11-20	2009-02-27	Янссен Фармацевтика Н. В.	7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
NZ546991A (en) *	2003-11-20	2010-01-29	Janssen Pharmaceutica Nv	6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors
EP1709012B1 (de) *	2003-12-05	2015-07-29	Janssen Pharmaceutica NV	6-substituierte 2-chinolinone und 2-chinoxalinone als inhibitoren von poly(adp-ribose)polymerase
EP1694653B1 (de) *	2003-12-10	2016-01-20	Janssen Pharmaceutica NV	6-(hetero-)cyclohexylalkyl substituierte 2-chinolinone/2-chinoxalinone als poly(adp-ribose) polymeraseinhibitoren
NZ547277A (en) *	2004-01-23	2009-08-28	Janssen Pharmaceutica Nv	Substituted quinolines and their use as mycobacterial inhibitors
US7550482B2 (en)	2004-02-27	2009-06-23	Merz Pharma Gmbh & Co. Kgaa	Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
TWI301760B (en) *	2004-02-27	2008-10-11	Merz Pharma Gmbh & Co Kgaa	Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US20060004001A1 (en) *	2004-02-27	2006-01-05	Merz Pharma Gmbh & Co., Kgaa	Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
WO2005121138A2 (en) *	2004-06-03	2005-12-22	Rigel Pharmaceuticals, Inc.	Heterotricyclic compounds for use as hcv inhibitors
KR101211950B1 (ko)	2004-06-30	2012-12-13	얀센 파마슈티카 엔.브이.	Ｐａｒｐ 저해제로서의 프탈아진 유도체
CA2569827C (en)	2004-06-30	2013-04-09	Janssen Pharmaceutica N.V.	Quinazolinedione derivatives as parp inhibitors
EA012837B1 (ru)	2004-06-30	2009-12-30	Янссен Фармацевтика Н.В.	Производные хиназолинона в качестве ингибиторов parp
GB0420722D0 (en) *	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
GB0420970D0 (en) *	2004-09-21	2004-10-20	Smithkline Beecham Corp	Novel triazoloquinoline compounds
MX2007003922A (es) *	2004-10-05	2007-06-07	Merz Pharma Gmbh & Co Kgaa	Nuevas propenonas ciclicas y aciclicas para tratar trastornos del sistema nervioso central.
US7608643B2 (en)	2005-03-09	2009-10-27	Schering Corporation	Compounds for inhibiting KSP kinesin activity
EP1863571A1 (de) *	2005-03-09	2007-12-12	Shering Corporation	Verbindungen zur hemmung der ksp-kinesin-aktivität
WO2007023242A1 (en) *	2005-08-24	2007-03-01	Merz Pharma Gmbh & Co. Kgaa	Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
EP1943247A1 (de) *	2005-08-25	2008-07-16	Merz Pharma GmbH & Co.KGaA	Tetrahydrochinolinone und ihre verwendung als modulatoren von metabotropenglutamatrezeptoren
EP2258359A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1928437A2 (de)	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenese mittels muscarinrezeptormodulation
AU2006298727B2 (en) *	2005-10-05	2011-11-17	F. Hoffmann-La Roche Ag	Naphthyridin derivatives
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
EP2314289A1 (de)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba-rezeptor-vermittelte modulation von neurogenese
DE602006009556D1 (de) *	2005-12-20	2009-11-12	Richter Gedeon Nyrt	Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
AR059898A1 (es)	2006-03-15	2008-05-07	Janssen Pharmaceutica Nv	Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
EP2026813A2 (de)	2006-05-09	2009-02-25	Braincells, Inc.	5-ht-rezeptor-vermittelte neurogenese
EP2377531A2 (de)	2006-05-09	2011-10-19	Braincells, Inc.	Neurogenese mittels Angiotensin-Modulation
WO2008028168A2 (en) *	2006-09-01	2008-03-06	Cylene Pharmaceuticals, Inc.	Serine-threonine protein kinase and parp modulators
WO2008030651A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
CA2668592C (en) *	2006-11-14	2016-04-19	Santen Pharmaceutical Co., Ltd.	Novel 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CA2678248C (en)	2007-03-08	2016-06-28	Janssen Pharmaceutica Nv	Quinolinone derivatives as parp and tank inhibitors
BRPI0812816B8 (pt)	2007-06-18	2021-05-25	Richter Gedeon Nyrt	compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmos
NZ584145A (en)	2007-09-14	2012-03-30	Ortho Mcneil Janssen Pharm	1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
CA2697399C (en)	2007-09-14	2016-01-19	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
ES2448870T3 (es) *	2007-10-26	2014-03-17	Janssen Pharmaceutica, N.V.	Derivados de quinolina como inhibidores de PARP
WO2009074607A1 (en)	2007-12-12	2009-06-18	Glaxo Group Limited	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
AU2009228945B2 (en) *	2008-03-27	2013-05-02	Janssen Pharmaceutica Nv	Quinazolinone derivatives as tubulin polymerization inhibitors
SI2271626T1 (sl)	2008-03-27	2015-03-31	Janssen Pharmaceutica, N.V.	Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
JP5547194B2 (ja)	2008-09-02	2014-07-09	ジャンセンファーマシューティカルズ，インコーポレイテッド．	代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
US9126946B2 (en)	2008-10-28	2015-09-08	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
ES2401691T3 (es) *	2008-11-28	2013-04-23	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN102439008B (zh)	2009-05-12	2015-04-29	杨森制药有限公司	1,2,4-***并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ596053A (en)	2009-05-12	2013-05-31	Janssen Pharmaceuticals Inc	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2815002C (en)	2010-11-08	2019-10-22	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2012062750A1 (en)	2010-11-08	2012-05-18	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103261195B (zh)	2010-11-08	2015-09-02	杨森制药公司	1,2,4-***并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
NZ703852A (en)	2012-07-27	2018-03-23	Biogen Ma Inc	Atx modulating agents
PL2909192T3 (pl)	2012-10-16	2017-09-29	Janssen Pharmaceutica Nv	Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T
ES2628365T3 (es)	2012-10-16	2017-08-02	Janssen Pharmaceutica N.V.	Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
AU2013331493A1 (en)	2012-10-16	2015-04-09	Janssen Pharmaceutica Nv	Heteroaryl linked quinolinyl modulators of RORyt
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
AU2014334619A1 (en)	2013-10-15	2016-04-21	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of RORyt
BR112016008258A2 (pt)	2013-10-15	2017-10-10	Janssen Pharmaceutica Nv	moduladores de ror?t de quinolinila
US9328095B2 (en)	2013-10-15	2016-05-03	Janssen Pharmaceutica Nv	Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en)	2013-10-15	2016-03-15	Janssen Pharmaceutica Nv	Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en)	2013-10-15	2016-08-02	Janssen Pharmaceutica Nv	Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en)	2013-10-15	2015-12-29	Janssen Pharmaceutica Nv	Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en)	2013-10-15	2020-02-11	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of RORγt
ES2748633T3 (es)	2014-01-21	2020-03-17	Janssen Pharmaceutica Nv	Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
KR20220049612A (ko)	2014-01-21	2022-04-21	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
MX2017016413A (es)	2015-06-12	2018-08-01	Axovant Sciences Gmbh	Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
CA2992518A1 (en)	2015-07-15	2017-01-19	Axovant Sciences Gmbh	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2017014201A1 (ja)	2015-07-17	2017-01-26	富士フイルム株式会社	含窒素複素環化合物
CA3048602A1 (en)	2016-12-27	2018-07-05	Fujifilm Corporation	Antitumor agent and bromodomain inhibitor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2526232A (en) *	1946-10-21	1950-10-17	Parke Davis & Co	Substituted hydantoins and methods for obtaining the same
GB1013224A (en) *	1962-06-21	1965-12-15	Ici Ltd	Heterocyclic aminoethanols
JPS5566560A (en) *	1978-11-14	1980-05-20	Yoshitomi Pharmaceut Ind Ltd	Quinolone derivative
US4348398A (en) *	1980-12-23	1982-09-07	Merck Sharp & Dohme (I.A.) Corp.	Quinolinyl ethanolamines
DE3276432D1 (en) *	1981-03-24	1987-07-02	Ciba Geigy Ag	Acyl quinolinone derivatives, processes for their preparation, pharmaceutical compositions containing them and their use
US4473132A (en) *	1981-11-25	1984-09-25	Schwing Robert F	Fire escape mechanism
GB8307831D0 (en) *	1983-03-22	1983-04-27	Fujisawa Pharmaceutical Co	Triazine derivatives
JPS6019767A (ja) *	1983-07-11	1985-01-31	Otsuka Pharmaceut Co Ltd	カルボスチリル誘導体を有効成分とする抗潰瘍剤
US4845100A (en) *	1985-04-12	1989-07-04	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same
JPH0696555B2 (ja) *	1986-07-31	1994-11-30	大塚製薬株式会社	カルボスチリル誘導体
JPH0776838B2 (ja) *	1988-10-05	1995-08-16	富士ゼロックス株式会社	電子写真感光体及び画像形成方法
CA2547947C (en) *	1990-11-30	2007-09-25	Masatoshi Chihiro	Azole derivatives as active superoxide radical inhibitors
PH31245A (en) *	1991-10-30	1998-06-18	Janssen Pharmaceutica Nv	1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
JPH06239858A (ja) *	1993-02-16	1994-08-30	Otsuka Pharmaceut Co Ltd	末梢血管拡張剤
US5475007A (en) *	1993-05-28	1995-12-12	The Regents Of The University Of California	1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
JPH0733743A (ja) *	1993-07-22	1995-02-03	Kyorin Pharmaceut Co Ltd	２−アリール−４−キノリノール誘導体
JPH08295690A (ja) *	1995-04-26	1996-11-12	Tokuyama Corp	クロメン化合物
EP0901489A1 (de) *	1996-05-20	1999-03-17	Merck & Co., Inc.	Gonadotropin releasing hormone-antagoniste
JP2001515839A (ja) *	1997-07-18	2001-09-25	ジョージタウン・ユニバーシティ	二環式向代謝性グルタミン酸受容体リガンド
CA2311131A1 (en) *	1997-11-21	1999-06-03	Nps Pharmaceuticals, Inc.	Metabotropic glutamate receptor antagonists for treating central nervous system diseases
EP1107962B1 (de) *	1998-08-27	2005-02-23	Pfizer Products Inc.	Quinolin-2-on-derivate verwendbar als antikrebsmittel
JP2000169450A (ja) *	1998-09-30	2000-06-20	Kyorin Pharmaceut Co Ltd	６―アリ―ルキノリンカルボン酸誘導体とその付加塩及びそれらの製造方法
SK286072B6 (sk)	1998-12-23	2008-02-05	Janssen Pharmaceutica N. V.	1,2-anelované chinolínové deriváty, spôsob ich prípravy, medziprodukty, farmaceutický prostriedok aich použitie
DE19859750A1 (de) *	1998-12-23	2000-06-29	Henkel Kgaa	Mittel zum Färben von keratinhaltigen Fasern
ID29584A (id) *	1999-02-11	2001-09-06	Pfizer Prod Inc	Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker
AU2001236100A1 (en)	2000-03-07	2001-09-17	Takeda Chemical Industries Ltd.	Vasoactive agents
UA76726C2 (uk) *	2000-10-02	2006-09-15	Янссен Фармацевтика Н.В.	Метаботропічні антагоністи рецептора глутамату, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб її одержання

2001
- 2001-09-25 UA UA2003032796A patent/UA76726C2/uk unknown
- 2001-09-25 AU AU2001293847A patent/AU2001293847B2/en not_active Ceased
- 2001-09-25 KR KR1020037002014A patent/KR100818965B1/ko not_active IP Right Cessation
- 2001-09-25 SK SK521-2003A patent/SK5212003A3/sk unknown
- 2001-09-25 CA CA002421782A patent/CA2421782A1/en not_active Abandoned
- 2001-09-25 BR BR0114253-4A patent/BR0114253A/pt not_active IP Right Cessation
- 2001-09-25 ES ES01974298T patent/ES2309095T3/es not_active Expired - Lifetime
- 2001-09-25 MX MXPA03002907A patent/MXPA03002907A/es unknown
- 2001-09-25 US US10/381,987 patent/US7115630B2/en not_active Expired - Fee Related
- 2001-09-25 JP JP2002532423A patent/JP2004510764A/ja active Pending
- 2001-09-25 AU AU9384701A patent/AU9384701A/xx active Pending
- 2001-09-25 PL PL36067701A patent/PL360677A1/xx not_active IP Right Cessation
- 2001-09-25 WO PCT/EP2001/011135 patent/WO2002028837A1/en active IP Right Grant
- 2001-09-25 EE EEP200300126A patent/EE05195B1/xx not_active IP Right Cessation
- 2001-09-25 EA EA200300428A patent/EA007464B1/ru not_active IP Right Cessation
- 2001-09-25 HU HU0302167A patent/HUP0302167A3/hu unknown
- 2001-09-25 CZ CZ20031145A patent/CZ20031145A3/cs unknown
- 2001-09-25 CN CNA018167179A patent/CN1703403A/zh active Pending
- 2001-09-25 IL IL15516301A patent/IL155163A0/xx unknown
- 2001-09-25 EP EP01974298A patent/EP1332133B1/de not_active Expired - Lifetime
- 2001-09-25 DE DE60134762T patent/DE60134762D1/de not_active Expired - Lifetime
- 2001-09-25 AT AT01974298T patent/ATE400558T1/de not_active IP Right Cessation
- 2001-09-25 NZ NZ524945A patent/NZ524945A/en not_active IP Right Cessation
- 2001-09-27 MY MYPI20014515A patent/MY147730A/en unknown
- 2001-10-01 AR ARP010104629A patent/AR035065A1/es unknown
2003
- 2003-03-24 HR HR20030229A patent/HRP20030229A2/hr not_active Application Discontinuation
- 2003-03-26 BG BG107672A patent/BG107672A/bg unknown
- 2003-03-31 ZA ZA200302515A patent/ZA200302515B/en unknown
- 2003-03-31 IL IL155163A patent/IL155163A/en not_active IP Right Cessation
- 2003-04-01 NO NO20031474A patent/NO325079B1/no not_active IP Right Cessation
2005
- 2005-05-20 US US11/133,678 patent/US7629468B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AR035065A1 (es)	2004-04-14
JP2004510764A (ja)	2004-04-08
ES2309095T3 (es)	2008-12-16
HRP20030229A2 (en)	2003-06-30
BR0114253A (pt)	2003-07-01
ATE400558T1 (de)	2008-07-15
SK5212003A3 (en)	2004-03-02
EA200300428A1 (ru)	2003-08-28
EE05195B1 (et)	2009-08-17
CZ20031145A3 (cs)	2003-12-17
ZA200302515B (en)	2004-06-30
MY147730A (en)	2013-01-15
NO20031474D0 (no)	2003-04-01
NZ524945A (en)	2005-01-28
AU9384701A (en)	2002-04-15
US7115630B2 (en)	2006-10-03
NO325079B1 (no)	2008-01-28
MXPA03002907A (es)	2003-06-24
WO2002028837A1 (en)	2002-04-11
UA76726C2 (uk)	2006-09-15
BG107672A (bg)	2004-01-30
CA2421782A1 (en)	2002-04-11
AU2001293847B2 (en)	2007-05-24
EA007464B1 (ru)	2006-10-27
IL155163A0 (en)	2003-10-31
IL155163A (en)	2009-08-03
EE200300126A (et)	2005-04-15
PL360677A1 (en)	2004-09-20
HUP0302167A3 (en)	2010-03-29
CN1703403A (zh)	2005-11-30
EP1332133A1 (de)	2003-08-06
US20040082592A1 (en)	2004-04-29
NO20031474L (no)	2003-05-05
KR100818965B1 (ko)	2008-04-04
KR20030036689A (ko)	2003-05-09
EP1332133B1 (de)	2008-07-09
US7629468B2 (en)	2009-12-08
HUP0302167A2 (hu)	2003-10-28
US20050209273A1 (en)	2005-09-22

Legal Events

Date	Code	Title	Description
2009-07-30	8364	No opposition during term of opposition

Publication	Publication Date	Title
DE60134762D1 (de)	2008-08-21	Metabotropische glutamatrezeptor-antagonisten
ATE368659T1 (de)	2007-08-15	Thrombinrezeptorantagonisten
DK1224175T3 (da)	2004-07-12	Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
NO20032861D0 (no)	2003-06-20	Heteroarylurea nevropeptid YY5-reseptorantagonister
NO20032503D0 (no)	2003-06-03	Fenyletenyl- eller fenyletynylderivater som glutamatreseptorantagonister
DK1309559T3 (da)	2006-10-02	4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
NO20025754L (no)	2002-11-29	IL-8 Reseptor-antagonister
DE69921351D1 (de)	2004-11-25	4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
DK1305319T3 (da)	2006-08-14	4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DE60112051D1 (de)	2005-08-25	Il-8 rezeptor antagonisten
ATE353215T1 (de)	2007-02-15	Il-8 rezeptor-antagonisten
ATE370114T1 (de)	2007-09-15	Zwitterionische tachykinin-rezeptor-antagonisten
DE50100358D1 (de)	2003-08-14	Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
MA25739A1 (fr)	2003-04-01	Antagonistes recepteurs il-8
MA25659A1 (fr)	2002-12-31	Antagonistes recepteurs il-8
SE0003996D0 (sv)	2000-11-01	Receptorantagonister
NO20024366D0 (no)	2002-09-12	IL-8 reseptorantagonister